Research Ethics Committee Reference Number	IRAS no	Full Name of Trial	Site Invitation date	Site selection date	HRA Approval date	Date site confirmed by Sponsor	Date site confirmed	Date when site ready to start	Date of First Patient Recruited	Reasons for not achieving the 70 day target from receipt of valid research application to 1st patient recruited										Study team comments	Reasons for delay correspond to:
										A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other		
16/NW/0162	191115	TRACON 105RC10: A Randomized Phase 2 Trial OF Axitinib and TRC105 Versus Axitinib Alone (Including A Lead-in Phase 1B Dose-Escalation Portion) In Patients with Advanced or Metastatic Renal Cell Carcinoma	02/02/2016	08/06/2016	09/08/2016	26/09/2016	26/09/2016			Y										Local capacity and capability not yet finalised. Significant delay caused by having to wait for MHRA approval for an IB amendment.	Sponsor
15/YH/0478	186697	REGENERATE: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	14/06/2016	04/07/2016	19/07/2016	27/07/2016	03/08/2016	29/09/2016		Y							Y				Capacity and Capability authorisation from imaging department was delayed following a clarification made on the imaging schedule at the Site Initiation Visit. As at 30.09.16 two patients have declined to take part.	Neither
16/YH/0157	204585	PLATO - PersonaLising Anal cancer radioTherapy dOse - Incorporating Anal Cancer Trials (ACT).ACT3, ACT4 and ACT5	21/07/2016	21/07/2016	20/07/2016															Local capacity and capability not completed within target timeframe.	NHS
16/SC/0147	183044	TRIMASTER V1: Randomised Double-Blind Crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on dual therapy with metformin and a sulphonylurea	20/05/2016	01/08/2016	07/07/2016								Y							Sponsor has delayed start date until early 2017 as they are unable to get the pharmacy supplies until the end of November 2016 at the earliest	Sponsor
16/LO/0570	196856	RIPCORD 2:A randomised controlled trial to compare routine pressure wire assessment with conventional angiography in the management of patients with coronary artery disease	24/05/2016	18/08/2016	17/08/2016	26/09/2016														Local capacity and capability not yet finalised. Still within target timeframe for first patient recruitment as at 30/9/16, but SIV that was scheduled for 13/10/16 has had to be cancelled due to a rail strike. Due to staff availability and further rail strikes the SIV is not expected to take place until mid-Nov, which is after the first patient target date.	Both
16/EE/0098	201052	DIASOLVE: A randomised, crossover investigation to evaluate and compare the effectiveness, safety and feasibility of a novel dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for measuring fractional flow reserve (FFR) using intra-coronary non-weight adjusted adenosine infusion with the standard intra-venous administration of adenosine, in subjects with intermediate coronary artery stenosis.	28/07/2016	18/08/2016	17/08/2016	06/09/2016	13/09/2016	21/09/2016	22/09/2016											70 day target met	Neither
16/SC/0159	195312	TWILIGHT: Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention	03/09/2015	09/09/2016	21/07/2016	21/09/2016	26/09/2016	29/09/2016												Still within target timeframe for first patient recruitment	Neither
16/LLO/1113	209455	GEMINI 2 (205543) A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naive adults	03/05/2016	13/09/2016	05/09/2016	13/07/2016	14/07/2016	21/09/2016												Sponsor confirmed 29/06/2016 that they did not wish to initiate UK and European sites until September 2016 (after USA data analysis). Green light now given, and still within target timeframe to recruit the first patient.	Neither
15/EM/0551	191168	IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial	12/04/2016	20/09/2016	07/07/2016	24/10/2016														Local capacity and capability not yet finalised. Still within target timeframe for first patient recruitment.	Neither
16/SC/0089	196789	Protective Ventilation with Veno-Venous Lung Assist in Respiratory Failure	22/09/2016	22/09/2016	20/06/2016															Local capacity and capability not yet finalised. Still within target timeframe for first patient recruitment.	Neither
16/LO/0585	200579	CASTING: An Open Label Study To Evaluate The Efficacy and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis Who Have a Suboptimal Response to An Adequate Course of Disease Modifying Treatment	18/03/2016	28/09/2016	13/06/2016	06/10/2016	12/10/2016	24/10/2016												Local capacity and capability not yet finalised, but we are working to the expected timeframe.	Neither